XML 32 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:    
Consolidated net loss $ (31,680,918) $ (19,533,679)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Gain on settlement of notes payable 0 (95,427)
Noncash stock compensation expense 11,600,014 11,970,284
Noncash stock expense associated with in-licensing agreement 0 1,211,250
Depreciation 5,805 1,558
Amortization of premium on investment securities 205,409 66,943
Change in fair value of notes payable 20,170 94,685
Changes in assets and liabilities:    
Increase in restricted cash (2,098) 0
Increase in other current assets (5,117,040) (2,383,969)
Increase in accrued interest receivable (104,797) (47,513)
Increase in other assets 0 (13,244)
Increase (decrease) in accounts payable and accrued expenses 4,018,767 (3,002,113)
Decrease in interest payable 0 (94,590)
Decrease in deferred revenue (76,191) (76,191)
Net cash used in operating activities (21,130,879) (11,902,006)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment (20,280) (3,165)
Investment in held-to-maturity long-term securities (18,324,355) (6,127,539)
Investment in held-to-maturity short-term securities (16,746,270) (3,090,469)
Proceeds from maturity of short-term securities 7,850,000 0
Net cash used in investing activities (27,240,905) (9,221,173)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from the exercise of warrants 992,644 1,602,060
Payment of notes payable 0 (677,778)
Proceeds from sale of common stock, net 51,984,879 16,791,408
Deferred financing costs paid (19,437) 0
Net cash provided by financing activities 52,958,086 17,715,690
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 4,586,302 (3,407,489)
Cash and cash equivalents at beginning of period 55,713,784 40,485,466
CASH AND CASH EQUIVALENTS AT END OF PERIOD 60,300,086 37,077,977
NONCASH TRANSACTIONS    
Accrued financing costs 47,797 0
Reclassification of deferred financing costs to additional paid-in capital $ (48,771) $ 0